Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27%…
Tag: extensivestage
46% reduction in the risk of disease progression or death, and 27%…
